The Q3 results are overshadowed by the casdatifan pipeline catalyst: PEAK-1 enrollment completion and PEAK-20 initiation are near-term milestones. The $288M equity raise provides funding into 2029 but diluted existing holders by ~11%. Watch for the PRISM-1 interim analysis in Q4 2026 and more mature ARC-20 data in 2027.
Drugs in focus
RCUS drug pipeline →quemliclustat
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 4-6 years minimum. Quemliclustat is in Phase 2 testing with primary completion estimated January 2027. If successful, it would need to advance to Phase 3 and then regulatory filing, putting potential approval/commercialization at least several years away.
- Next catalyst
- None dated
What to watchThe next hard catalyst for quemliclustat is the Phase 2 primary completion readout from trial NCT05329766, estimated for January 2027. However, this is a secondary pipeline asset at Arcus, the stock's primary value driver is casdatifan (HIF-2α inhibitor). Watch for topline data from the GI malignancy trial in early 2027, but expect the stock to move more on casdatifan and domvanalimab catalysts than on quemliclustat alone.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $17.69entry
- T+1 · 11d ago +3.34%α +3.02% · $18.28
- T+5 · 5d ago +0.45%α −2.84% · $17.77
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
The company highlighted strong clinical data for its lead candidate casdatifan and extended its cash runway into 2029 following a $288M October equity offering, but revenue declined 65% YoY due to the wind-down of the Gilead collaboration.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $9M, down from $26M YoY, primarily due to lower Gilead collaboration revenue
- Cash, cash equivalents and marketable securities of $694M at quarter end; plus $288M gross from October equity offering extends runway into 2029
- Full-year 2026 GAAP revenue guidance of $70M-$75M
- PEAK-1 Phase 3 enrollment expected to complete in 2-3 months; PEAK-20 Phase 3 to initiate by year-end 2026
- Multiple data readouts for casdatifan expected in 2027
- October 2026 equity offering of 14.3M shares at $17.50 per share raised $250M gross ($234.5M net)
Financial Impact
Revenue declined 65% YoY to $9M; net loss improved to $128M from $135M; cash burn rate remains high but extended by $288M equity raise
Risk Factors
- Revenue decline driven by Gilead collaboration wind-down, with no near-term product revenue
- Significant dilution from October 2026 equity offering (14.3M new shares)
- Clinical-stage biotech with no approved products; casdatifan and quemliclustat are investigational
- Cash burn remains substantial; reliance on further financing if milestones are delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001724521-26-000056 |
| Document: 0001724521-26-000056-index-headers.html | 0001724521-26-000056 |
| Document: 0001724521-26-000056-index.html | 0001724521-26-000056 |
| Document: 0001724521-26-000056.txt | 0001724521-26-000056 |
| 8-K Data (Synthetic) | 0001724521-26-000056 |
Track record
13 reports on RCUS
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 Now $16.86 −0.53% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $18.95 to $16.86 Now $16.86 −11.03% ▼ −11.03% −9.34% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $17.69 to $17.77 Now $16.86 −4.69% ▲ +0.45% −2.84% vs SPY
- Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 Now $16.86 +5.07% ▼ −2.42% −3.68% vs SPY
- Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 Now $16.86 +9.06% ▲ +1.89% +1.33% vs SPY
- Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 Now $16.86 +12.91% ▲ +3.87% +4.58% vs SPY
- Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 Now $16.86 −12.91% ▼ −3.87% −4.58% vs SPY
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 Now $16.86 −29.01% ▼ −23.62% −23.70% vs SPY
- Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 Now $16.86 −41.70% ▼ −7.88% −7.32% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 Now $16.86 −36.66% ▼ −7.79% −7.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers